Objective-SFRP5 (secreted frizzled-related protein 5) is an endogenous inhibitor of WNT5A (wingless-type family member 5a), which has been implicated in atherosclerosis. However, contradictory results have been reported about the role of SFRP5 in atherosclerosis. We aimed to investigate whether SFRP5 could restore WNT5A-induced endothelial dysfunction in vitro and ex vivo. In addition, we sought to determine whether the serum concentration of SFRP5 is associated with atherosclerosis in humans. Approach and Results-We measured endothelium-dependent vasorelaxation in the isolated thoracic aorta of Sprague-Dawley rats. In addition, we measured intracellular nitric oxide (NO) in human endothelial cells. The protein abundance of total and phosphorylated JNK (c-Jun N-terminal kinase), AKT (protein kinase B), and endothelial NO synthase was analyzed in human endothelial cells. Circulating SFRP5 and WNT5A levels and brachial-ankle pulse wave velocity were measured in 282 human subjects with type 2 diabetes mellitus. SFRP5 dose dependently restored Wnt5-induced impaired vasorelaxation in rat thoracic aorta by an endothelial NO synthase-dependent mechanism. SFRP5 treatment restored the WNT5A-induced reduction of NO production via endothelial NO synthase in human endothelial cells. WNT5A-induced changes in the phosphorylation of JNK, AKT, and endothelial NO synthase were ameliorated with SFRP5 administration. In humans with type 2 diabetes mellitus, the serum SFRP5 concentration positively correlated with brachial-ankle pulse wave velocity (r=0. 
W NT (wingless-type family member) proteins, which consist of 19 related proteins, are secreted glycoproteins acting as signaling molecules 1 that have been implicated in inflammation 2 and proliferation, differentiation, 3 and migration. 4 WNT5A, a noncanonical member of the Wnt family proteins, has been particularly investigated in regard to the pathogenesis of atherosclerosis. 5 For instance, WNT5A expression has been demonstrated to be elevated in murine and human atherosclerotic lesions, and its expression was coincident with that of Toll-like receptors. 6, 7 In addition, WNT5A-mediated signaling stimulates endothelial cell proliferation 8 and vascular calcification, 9 both of which are related to the pathogenesis of atherosclerosis. Taken together, these previous findings suggest that WNT5A could be involved in the development of atherosclerosis by influencing endothelial and vascular function besides inflammatory responses during atherosclerosis.
SFRP5 (secreted frizzled-related protein 5), which is an antiinflammatory adipokine and an endogenous inhibitor of WNT5A signaling, has been suggested to play critical roles in obesity, 10 insulin resistance, 11 and diabetes mellitus. 12, 13 Previous studies have consistently reported that it has an anti-inflammatory effect through the suppression of the noncanonical WNT5A/JNK (c-Jun N-terminal kinase) signaling pathway. 10, 14, 15 However, data on the relationship between WNT5A and SFRP5 in humans are limited and inconsistent. [15] [16] [17] [18] Furthermore, little is known about the role of SFRP5 in the development of endothelial dysfunction, which is an early pivotal event in the pathogenesis of atherosclerosis that is characterized by an imbalance between endothelium-dependent vasorelaxation and vasoconstriction. 19, 20 Here, we examined the following issues: (1) whether WNT5A causes the impairment of endothelial vasorelaxation, (2) if so, whether SFRP5 can antagonize this effect of WNT5A on endothelial vasorelaxation, and (3) whether this effect of SFRP5 is associated with the inhibition of the WNT5A/JNK pathway. Furthermore, we also aimed to investigate whether the serum concentrations of SFRP5 and WNT5A were associated with a surrogate measure of atherosclerosis in humans.
Materials and Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Cell Culture and Treatment
Human umbilical vein endothelial cells (HUVECs) and human aortic endothelial cells (HAECs) from the 5 different donors were obtained from Lonza Inc (CC-2517A for HUVECs and CC-2535 for HAECs; Walkersville, MD) and maintained in endothelial basal medium (CC-3162; Lonza) supplemented with various growth factors that are required for the growth of endothelial cells and 2% fetal bovine serum at 37°C in a humidified incubator supplemented with 5% CO 2 . In all experiments, cells were used at 6 or fewer passages.
Recombinant WNT5A (No. 645-WN; R&D Systems, Minneapolis, MN) and SFRP5 (No. 6266-SF; R&D Systems) were administered to the cells for the indicated amount of time. Phosphate-buffered saline was used as the vehicle. Cells were transferred to the medium containing 2% fetal bovine serum and incubated in media containing various concentrations of SFRP5 for the indicated amount of time before treatment with WNT5A. The endotoxin level of the recombinant WNT5A is <1.0 EU per 1 μg/mL of the protein by the Limulus amebocyte lysate method and is suitable for animal experiment.
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Nitric Oxide Detection
Endothelial nitric oxide (NO) levels were visualized and quantified using 4,5-diaminofluorescein diacetate, which is a membrane-permeable fluorescent indicator for NO. 22 Endothelial cells were loaded with 4,5-diaminofluorescein diacetate solution in Hanks' Balanced Salt Solution (1 µmol/L, 30 minutes) at 37°C in darkness and treated with recombinant WNT5A protein or vehicle. Where indicated, SFRP5 or nitro-ʟ-arginine (ʟ-NNA; Sigma-Aldrich, St. Louis, MO), which is a nitric oxide synthase (NOS) inhibitor, 23 was added 30 minutes before loading the cells with 4,5-diaminofluorescein diacetate probe and incubated together with WNT5A treatment. The cells were then washed once in phosphate-buffered saline and visualized using confocal microscopy (LSM710; Carl Zeiss, Oberkochen, Germany) at ×40 magnification. All images were captured at the same exposure time and corrected for background fluorescence. Fluorescent intensity was quantified with a fluorescence plate reader (VICTOR X2; PerkinElmer, Waltham, MA). After incubation with the primary antibodies, the membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibodies (Vector Laboratories, Burlingame, CA). Immunoreactive bands were visualized by enhanced chemiluminescence (RPN2106; Amersham Bioscience, Buckinghamshire, United Kingdom). Relative protein abundance was quantified using ImageJ (National Institutes of Health, Bethesda, MA) and normalized versus internal controls.
Western Blotting Analysis
Animals
Eight-week-old male Sprague-Dawley (SD) rats (Orient Bio, Sungnam, Korea) weighing 250 to 300 g were housed in cages containing 4 rats per cage and allowed ad libitum access to water and food. We used only male SD rats to minimize the gender effect on the NO release from the aorta. 24, 25 All experimental procedures were approved by the Institutional Animal Care and Use Committee of Asan Institute of Life Sciences.
Ex Vivo Measurement of EndotheliumDependent Vasorelaxation
Endothelium-dependent vasorelaxation was measured using an isometric force-displacement transducer (KG D-7806; Hugo Sachs Elektronik, Hugstetten, Germany) as described previously. 26 The thoracic aorta was excised from SD rats after euthanization with pentobarbital and then cleaned to remove fat and adhering tissue. The vessel was cut into several individual ring segments 2 to 3 mm in width and suspended from a force-displacement transducer in a tissue bath. Ring segments were washed in Krebs-Henseleit buffer (118 mmol/L NaCl, 4.6 mmol/L KCl, 27.2 mmol/L NaHCO 3 . SFRP5 was applied to the segments for 1 hour and then they were exposed to WNT5A for 16 hours. The submaximal contraction of the aortic ring was induced by treatment with 300 µmol/L phenylephrine. When vascular tension reached a plateau, acetylcholine (from 10 -9 to 10 -5 mol/L) was added serially to the bath to induce endothelium-dependent vasorelaxation. Vascular relaxation data were calculated as the percentage of the maximal vasorelaxation, and the dose-response profile for each experiment was analyzed. 26 ʟ-NNA was used to determine whether NO derived from NOS was responsible for mediating the vasorelaxative effects of SFRP5.
Human Subjects
A total of 282 subjects with type 2 diabetes mellitus were included in this study. We consecutively recruited patients who visited the diabetes mellitus clinic at the Asan Medical Center, Seoul, Republic of Korea, for the treatment of diabetes mellitus and evaluation of microand macrovascular complications of diabetes mellitus between November 2012 and January 2014. Before starting the recruitment process, the study was registered in the Clinical Research Information Service (URL: http://cris.nih.go.kr. Unique identifier: KCT0000598). All subjects provided written informed consent. This study was approved by the Institutional Review Board of the Asan Medical Center. PPARγ (peroxisome proliferator-activated receptor γ) agonists such as thiazolidinedione affect Wnt/β-catenin signaling via various mechanisms, 27 and therefore patients treated with thiazolidinedione were excluded from the study.
Anthropometric and Laboratory Measurements
Height and weight were obtained while subjects wore light clothing without shoes. The waist circumference (cm) was measured midway between the costal margin and the iliac crest at the end of a normal expiration. The blood pressure (BP) was measured on the right arm after a rest of ≥5 minutes.
After overnight fasting, early morning blood samples were drawn from the antecubital vein into vacuum tubes and subsequently analyzed by a central, certified laboratory at the Asan Medical Center. Fasting plasma glucose was measured by the glucose oxidase method using a 200FR Neo chemistry analyzer (Toshiba Medical Systems, Tokyo, Japan). Hemoglobin A1c was measured by high-performance liquid chromatography using a Variant II Turbo system (Bio-Rad Laboratories, Hercules, CA). Fasting total cholesterol, HDL-C (highdensity lipoprotein cholesterol), LDL-C (low-density lipoprotein cholesterol), TG (triglyceride), uric acid, AST (aspartate aminotransferase), and ALT (alanine aminotransferase) were measured by an enzymatic colorimetric method (Toshiba). HsCRP (high-sensitivity C-reactive protein) was measured using the immunoturbidimetric method (Toshiba). Serum insulin was measured by an immunoradiometric assay (TFB Co, Tokyo, Japan). Homeostatic model assessment for insulin resistance (HOMA-IR) has been suggested to be a useful test for the evaluation of insulin resistance even in patients with type 2 diabetes mellitus treated with insulin secretagogues or insulin. 28 All enzyme activities were measured at 37°C. HOMA-IR was calculated according to the following equation: HOMA-IR=[Insulin (μU/ mL)×fasting plasma glucose (mmol/L)]/22.5.
The extent of albuminuria was determined from the urinary albumin:creatinine ratio which was measured by a photometric method using the Integra 800 system (Roche Diagnostics, Indianapolis, IN) in a random spot urine collection. Creatinine was measured using the Jaffe method, and the estimated glomerular filtration rate (eGFR) was calculated using the modified Modification of Diet in Renal Disease equation.
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Measurement of Serum Concentrations of SFRP5, WNT5A, and Total Adiponectin
Fasting venous blood samples were centrifuged, and the supernatants were carefully collected to exclude cell components. All samples with hemolysis or clotting were discarded. Serum samples were stored at −80°C until use. The serum concentrations of SFRP5 and WNT5A were measured with competitive ELISA kits (SEC842Hu for serum SFRP5 and SEP549Mi for serum WNT5A; both kits from Cloud-Clone Corp, Houston, TX) according to the manufacturer's instructions. The lower detection limit of each kit is typically <0.059 ng/mL, and no significant cross-reactivity or interference between human SFRP5 or WNT5A and analogs was observed. The intra-and interassay coefficients of variation of the ELISA kits were <10.0% and <12.0%, respectively. The serum total adiponectin concentration was also measured using commercially available ELISA kits (Adipogen, Seoul, South Korea), with intra-and interassay coefficients of variation of <4.0% and <6.0%, respectively. Samples were assayed in duplicate, and all results were reported as mean values.
Measurement of Brachial-Ankle Pulse Wave Velocity
The measurement of brachial-ankle pulse wave velocity (baPWV), which is an index of the elastic properties of large arteries, 30 and the ankle-brachial index was determined using an automatic waveform analyzer (VP-1000; Colin Co, Komaki, Japan) with well-documented validity and reproducibility (coefficient of variation=3.31% and reproducibility coefficient=0.947). Volume waveforms for the brachium and ankle were stored using a sampling time of 10 s with automatic gain analysis and quality adjustment. The time interval between the fronts of the brachial and ankle waveforms was defined as the time interval between the brachium and ankle (△Tba). The distance between sampling points of baPWV was calculated automatically according to the height of the subject. The path lengths from the suprasternal notch to the brachium (Lb) and from the suprasternal notch to the ankle (La) were automatically obtained based on the subject's height. The baPWV was calculated using the following equation: baPWV=(La−Lb)/△Tba (cm/s) and was obtained after at least 5 minutes of rest. We used the mean of the right and left baPWV measurements as a marker of arterial stiffness. All the study subjects had an ankle-brachial index between 0.95 and 1.3, which ensured the accuracy of the baPWV measurements. 31 
Statistical Analysis
All statistical analyses were performed with SPSS version 19.0 for Windows (SPSS Inc, Chicago, IL). Data are expressed as means±SD for continuous variables and proportion (%) for categorical variables. Comparisons between 2 groups or among multiple groups were performed by independent Student's t test or 1-way ANOVA followed by a post hoc analysis using Tukey multiple comparison test, respectively. Variables that were not normally distributed were expressed as median (interquartile range) and compared using the Kruskal-Wallis test with Dunn post hoc test.
In human subjects, the correlation between serum SFRP5 and various parameters, including baPWV, was evaluated by Pearson correlation analysis. A logarithmic (log) transformation of values showing a skewed distribution was performed before the correlation analysis. The association between the mean baPWV and serum SFRP5 concentration was investigated by backward multiple linear regression, with mean baPWV serving as the dependent variable. All independent variables in the multiple linear regression were tested for multicollinearity; if the variance inflation factor exceeded 10, the variable was considered to be collinear. A 2-tailed P value of <0.05 was regarded as statistically significant.
Results
Effects of WNT5A and SFRP5 on EndotheliumDependent Vasorelaxation in Isolated Aorta
In aortic rings isolated from SD rats, acetylcholine (Ach; an endothelium-dependent vasorelaxation agent) induced a concentration-dependent vasorelaxation effect. At the maximal concentration studied (10 −5 mol/L), Ach caused 98.2±3.0% vasorelaxation in aortic ring segments ( Figure 1A ). Treatment with 50 and 100 ng/mL WNT5A significantly attenuated endothelium-dependent vascular relaxation in the isolated aorta in a concentration-dependent fashion ( Figure 1A ). To investigate whether SFRP5 could reverse WNT5A-induced impaired vasorelaxation in aortic tissue, we administered 2 doses of SFRP5 (100 and 200 ng/mL) to the aortic tissue before the treatment with 100 ng/mL of WNT5A. The administration of SFRP5 significantly improved vasorelaxation as evidenced by a downward shift of the concentration-dependent curve in response to Ach ( Figure 1B) . The single SFRP5 treatment did not demonstrate any effect on endothelium-dependent vascular relaxation (data not shown).
Effects of WNT5A and SFRP5 on NO Production in Human Endothelial Cells
Next, to evaluate whether the effects of WNT5A and SFRP5 on endothelium-dependent vasorelaxation in isolated aorta were mediated through the endothelial production of NO, we measured the production of NO by quantitative immunofluorescence in human endothelial cells. The treatment of HUVECs with WNT5A (100 ng/mL, 4 hours) resulted in a decreased endothelial production of NO (Figure 2A, bottom left) . To gain insight into the potential role of SFRP5 in the endothelial production of NO, we pretreated HUVECs with SFRP5 (200 ng/mL) for 30 minutes before the treatment with WNT5A. As shown in Figure 2A , bottom right, the treatment of endothelial cells with SFRP5 reversed the WNT5A-induced suppression of NO production. The single SFRP5 treatment without WNT5A caused no change in the endothelial production of NO (Figure 2A, top right) . These results suggested that SFRP5 regulated the endothelial production of NO by inhibiting WNT5A signaling. In addition, SFRP5 increased the endothelial production of NO in a dose-dependent manner ( Figure 2B ).
Similarly, SFRP5 restored the WNT5A-induced suppression of endothelial NO production in a dose-dependent manner in HAECs ( Figure I in the online-only Data Supplement).
To investigate whether NOS was responsible for the altered endothelial production of NO, we measured the endothelial production of NO in the presence or in the absence of ʟ-NNA. The pretreatment with ʟ-NNA abolished the restorative effect of SFRP5 on the decreased production of NO by WNT5A in HUVECs ( Figure 3A ) and in HAECs ( Figure II in the onlineonly Data Supplement). The single treatment of ʟ-NNA, an NOS inhibitor, also resulted in a decreased endothelial production of NO ( Figure 3A) and an impaired vascular relaxation in the isolated aorta ( Figure 3B) . Similarly, in ex vivo aortic rings, ʟ-NNA pretreatment significantly abrogated the vasodilatory effect of SFRP5 ( Figure 3C ). Collectively, these data suggested that SFRP5 restored the WNT5A-induced endothelial dysfunction through the upregulation of endothelial NO production in an NOS-dependent manner.
Finally, to investigate whether SFRP5 affected eNOS activation through the regulation of WNT5A/JNK signaling, we evaluated the effect of SFRP5 on the abundance of total and phosphorylated JNK and AKT and eNOS in human endothelial cells. A Western blot analysis demonstrated that WNT5A induced an increase in JNK phosphorylation and a sequential decrease in the phosphorylation of AKT and eNOS in HUVECs (Figure 4) . However, the pretreatment with SFRP5 led to a significant decrease in JNK phosphorylation and the recovery of AKT phosphorylation in HUVECs, which eventually reversed the WNT5A-induced impairment in eNOS activation (Figure 4) . We repeated Western blot analysis of proteins involved in WNT5A/JNK signaling pathways in HAECs and could obtain the similar results ( Figure III in the online-only Data Supplement). Taken together, these results suggested that the impact of SFRP5 on eNOS activation is mediated by inhibiting the WNT5A/JNK signaling pathway. In aortic rings isolated from Sprague-Dawley (SD) rats, acetylcholine (Ach; an endothelium-dependent vasorelaxation agent) induced a concentration-dependent vasorelaxation effect. Endothelium-dependent vasorelaxation was measured by the method described in the Materials and Methods. Data are shown as the means±SD of at least 5 independent experiments. A, WNT5A (50 and 100 ng/mL, 16 h) induced vasoconstriction in the isolated aorta in a dose-dependent manner. *P<0.05 vs untreated control, †P<0.05 vs WNT5A 50 ng/ mL group. B, SFRP5 (100 and 200 ng/mL, 1 h before the exposure to WNT5A) resolved the WNT5A-induced impairment in vasorelaxation. *P<0.05 vs untreated control, †P<0.05 vs WNT5A (100 ng/mL) alone group, ‡P<0.05 vs WNT5A (100 ng/mL)+SFRP5 (100 ng/mL) group. June 2018
Clinical and Biochemical Characteristics of the Human Subjects
To investigate the relationship of SFRP5 and WNT5A with atherosclerosis in humans, we measured the serum concentrations of SFRP5 and WNT5A in human subjects with type 2 diabetes mellitus. The average age of the study subjects was 58.0±9.0 years, and the average body mass index was 25.9±3.4 kg/m 2 . The mean concentrations of serum SFRP5, WNT5A, and total adiponectin were 9.24±4.61 ng/mL, 0.27±0.19 ng/mL, and 9.15±4.67 μg/mL, respectively. The serum concentration of WNT5A was too low to measure in 43 subjects out of total 282 subjects. The clinical and biochemical characteristics of the study subjects according to the serum SFRP5 tertile (ie, T1≤7.56 ng/mL, T2=7.57-10.42 ng/mL, and T3≥10.43 ng/mL) are shown in Table I in the online-only Data Supplement. Several variables including age, body mass index, waist circumference, systolic BP, diastolic BP, history of cardiovascular disease (CVD), duration of diabetes mellitus, percentage of subjects taking antihypertensive medications or statin, fasting plasma glucose, hemoglobin A1c, total cholesterol, TG, LDL-C, HDL-C, uric acid, AST, ALT, hsCRP, urinary albumin:creatinine ratio, eGFR, HOMA-IR, WNT5A, and total adiponectin were similar among the 3 groups (Table I in the online-only Data Supplement). A higher number of male subjects and current smokers were included in the highest serum SFRP5 tertile group (P=0.018 and 0.015, respectively). Mean baPWV linearly increased (P=0.032) across increasing serum SFRP5 tertile categories (Table I in the online-only Data Supplement). Table 1 shows the correlation between the serum concentration of SFRP5 or WNT5A and various glucometabolic parameters. In the Pearson correlation analysis, SFRP5 concentration showed a negative correlation with eGFR (r=−0.175; P=0.007). None of the other variables examined showed a significant correlation with the serum SFRP5 concentration ( Table 1) . The serum WNT5A concentration positively correlated with diastolic BP (r=0.143; P=0.027) and log-transformed TG (r=0.127; P=0.049; Table 1 ).
Correlation Between the Serum Concentration of SFRP5 or WNT5A and Various Glucometabolic Parameters
Association Between the Serum Concentration of SFRP5 or WNT5A and baPWV
In the Pearson correlation analysis, the serum SFRP5 concentration positively correlated with baPWV (r=0.146; P=0.024). The correlation between the serum SFRP5 concentration and baPWV was significant even after adjusting for the WNT5A concentration (r=0.145; P=0.025).
A (Table II in the online-only Data Supplement). A multivariate linear regression analysis was performed using multiple models, and the serum SFRP5 concentration was independently associated with baPWV in all models (Table 2 ).
Discussion
Our findings demonstrated that SFRP5 exerted a vasorelaxant effect and that it was involved in the regulation of NO through its inhibitory effect on WNT5A/JNK signaling in vascular endothelial cells. In addition, we showed that the serum SFRP5 concentration was significantly and positively associated with arterial stiffness in subjects with type 2 diabetes mellitus, and this association was independent of conventional cardiovascular risk factors.
SFRP5 is a novel adipokine with salutary effects on metabolic dysfunction similar to those of adiponectin, one of the most representative adipokines, which exerts anti-inflammatory and antiatherogenic effects [32] [33] [34] [35] by controlling the activity of inflammatory cells within adipose tissue. 10 Although it is well established that SFRP5 is an anti-inflammatory secreted adipokine, 10 human studies on the functions of SFRP5 in CVD have given rise to conflicting data, making it uncertain. 17, 18 Miyoshi et al 17 reported that the serum SFRP5 concentration in patients with coronary artery disease (CAD) was significantly lower than that in non-CAD patients and the severity of CAD negatively correlated with the serum SFRP5 concentration in the CAD cohort. In contrast, another follow-up study in China demonstrated that an increased SFRP5 concentration was significantly associated with the occurrence of major adverse cardiac events. 18 In our study, the serum SFRP5 concentration was significantly and positively associated with arterial stiffness in patients with type 2 diabetes mellitus ( Table 2) . This association could be caused by the action of SFRP5 as a compensatory factor to counteract metabolic stress during the development of atherosclerosis, considering our ex vivo finding that SFRP5 treatment exerted a vasorelaxative effect on the isolated thoracic aorta of rats and in vitro finding that SFRP5 treatment restored NO production by antagonizing the WNT5A/JNK pathway in endothelial cells.
Mechanistically, our present study provides the first direct evidence that SFRP5 exerts its vasorelaxant function by Figure 3 . Nitro-ʟ-arginine (ʟ-NNA) attenuated the restorative effect of SFRP5 (secreted frizzled-related protein 5) on the nitric oxide (NO) production and the vasodilator effect of SFRP5. Human umbilical vein endothelial cells (HUVECs) were treated with WNT5A (winglesstype family member 5A), SFRP5, and ʟ-NNA at the described doses and for the indicated durations. The production of NO was measured by quantitative immunofluorescence in HUVECs. The bar graph represents the mean values±SD of at least 5 independent experiments. Endothelium-dependent vasorelaxation was measured by the method described in the Materials and Methods. A, The pretreatment with ʟ-NNA (500 µmol/L) abolished the restorative effect of SFRP5 on the NO production (bottom center, green). *P<0.05 vs untreated control, †P<0.05 vs WNT5A alone (100 ng/mL) group, ‡P<0.05 vs WNT5A (100 ng/mL)+SFRP5 (200 ng/mL) group. B, Single treatment of ʟ-NNA (500 µmol/L) significantly suppressed vasorelaxation. *P<0.05 vs. untreated control, †P<0.05 vs WNT5A alone (100 ng/mL) group. C, ʟ-NNA (500 µmol/L) significantly abolished the vasodilatory effect of SFRP5. *P<0.05 vs untreated control, †P<0.05 vs WNT5A alone (100 ng/mL) group, ‡P<0.05 vs WNT5A (100 ng/mL)+SFRP5 (200 ng/mL) group.
increasing endothelial NO production via the WNT5A/JNK signaling pathway. Ouchi et al 10 previously showed that the adipose tissues of obese rodents and humans had a decreased level of SFRP5 expression and higher levels of WNT5A expression. Furthermore, SFRP5-deficient mice displayed highly activated JNK when fed a high-calorie diet, indicating that SFRP5 neutralized WNT5A-mediated noncanonical JNK activation in adipose tissues. 10 However, the mechanisms by which SFRP5 exerts its protective effects on the vasculature have not been well elucidated. To dissect the underlying mechanisms responsible for SFRP5-induced vascular dilation, we used cultured human endothelial cells and measured the expression of various signaling molecules that are potentially involved in NO production. eNOS is the enzyme that produces endothelium-derived NO. 36 It was previously reported that the serine/threonine protein kinase AKT can directly phosphorylate and activate eNOS, leading to NO production. 36 In recent experiments using HAECs, WNT5A treatment abrogated the insulin-stimulated activating phosphorylation of AKT and correspondingly reduced the insulin-stimulated NOS activity, indicating that WNT5A/JNK activation contributed to endothelial dysfunction and impaired NO production by inhibiting the AKT-dependent phosphorylation of eNOS. 37 Our results demonstrated that SFRP5 inhibited JNK phosphorylation while enhancing AKT/eNOS phosphorylation in WNT5A-treated endothelial cells (Figure 4 ; Figure III in the online-only Data Supplement). In addition, we showed that the vasorelaxant effect of SFRP5 was abolished by ʟ-NNA, an NOS inhibitor ( Figure 3C ). Collectively, these results implied that SFRP5 restored the WNT5A-induced endothelial dysfunction through the inhibition of the WNT5A/JNK pathway and the upregulation of endothelial NO production.
In this study, the serum WNT5A concentration positively correlated with several variables that are associated with insulin resistance (diastolic BP, fasting plasma glucose, TG, and uric acid), whereas it was inversely correlated with HDL-C (Table 1) , although some of the results had a borderline statistical significance. These findings agree with previous studies that identified WNT5A as one of the culprit molecules contributing to insulin resistance. 37, 38 However, we did not observe a significant association between the serum WNT5A concentration and baPWV in our cohort. Some researchers have suggested that circulating WNT5A is not a reliable marker for metabolic disorders 39, 40 because WNT5A is barely detectable in the human circulation 11,39 because of its autocrine or paracrine manner of action. 39, 41 In line with the previous studies, the serum concentration of WNT5A was too low to measure in 43 subjects in our study population. Previously, Carstensen et al 11 reported similar results of serum Wnt5a concentrations below the detection limit (0.02 ng/mL) in 81% of their study participants. These lower concentrations of WNT5A in the circulation could limit the effect of antagonizing WNT5A/JNK signaling pathway. However, considering autocrine or paracrine acting manner of WNT5A 41, 42 and its increased expression in atherosclerotic lesions as previously reported, 6, 7, 43 the increased WNT5A in the localized lesion, not in the circulation, would be critical and WNT5A could be a therapeutic target in atherosclerosis and metabolic dysfunction.
Previous studies evaluating the effect of recombinant SFRP5 used the dosage of 50 to 1000 ng/mL. [44] [45] [46] We found that 200 ng/mL of recombinant SFRP5 was effective to inhibit Wnt5a-induced suppression of NO production and vascular relaxation. However, in human subjects, the circulating SFRP5 level was lower than the dosage we used in our in vitro study. These findings suggest that a higher concentration of SFRP5 might be needed to ameliorate the endothelial dysfunction in metabolically unfavorable conditions. In addition, we observed that the serum SFRP5 concentration negatively correlated with eGFR. Although it can be assumed that the renal impairment represented by a low eGFR leads to a decreased excretion of SFRP5, further studies are needed to verify the association between kidney function and SFRP5 excretion.
This study had several important limitations. First, we used healthy aorta from SD rats, which could limit the interpretation of our result in terms of atherosclerosis, although we tried to reproduce the atherosclerotic milieu by treating the aorta with WNT5A, which has been demonstrated to be closely related to the pathogenesis of atherosclerosis and metabolic dysfunction. 37 Additional studies using atherosclerotic arteries especially from diabetic rats will be required to ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; hbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment for insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; NS, not significant; SFRP5, secreted frizzled-related protein 5; TG, triglyceride; UACR, urinary albumin:creatinine ratio; WC, waist circumference; and WNT5A, wingless-type family member 5a. *Logarithmic transformation was performed.
confirm the contribution of SFRP5 in atherosclerosis. Second, although we suggested that SFRP5 exerts its restorative effect on the WNT5A-induced impairment of NO production and vasorelaxation through inhibiting WNT5A/JNK pathway, further studies would be needed to prove the causal relationship between SFRP5 and WNT5A/JNK signaling and to investigate the possibility that SFRP5 might work by antagonizing other WNT proteins besides WNT5A. Third, because of its cross-sectional nature, we could not infer a causal relationship between an increased circulating SFRP5 concentration and the development of CVD. Additional experimental works or prospective studies would be required to infer a causal relationship between an increased circulating SFRP5 levels and the development of CVD, as the increased SFRP5 in circulation could be a consequence of metabolic derangement, not a direct cause of CVD. Fourth, we used baPWV as a surrogate marker of arterial stiffness rather than carotid-femoral PWV, which is the gold standard measure of PWV. 47 However, in a previous report, baPWV and carotid-femoral PWV both exhibited a similar extent of association with established risk factors for CAD and clinical cardiovascular events. 48 Last, this study included only Korean subjects with type 2 diabetes mellitus; therefore, our results may not fully apply to the general population or other ethnic populations.
Despite these limitations, our study showed an association between SFRP5 and arterial stiffness in human subjects and simultaneously provided a molecular mechanism underlying the vasodilative function of SFRP5 through a series of in vitro and ex vivo experiments. The effect of SFRP5 as a vasodilative agent was significant, and our findings represent an additional step toward attaining a profound understanding of the clinical importance of this anti-inflammatory adipokine.
In conclusion, we identified SFRP5 as a novel vasodilative adipokine that induces endothelial NO production by antagonizing the WNT5A/JNK signaling pathway. We also demonstrated that an elevated serum SFRP5 concentration was significantly associated with arterial stiffness in human subjects with type 2 diabetes mellitus, indicating that SFRP5 might be important in the regulation of vascular function in humans. Finally, our identification of the significant relevance of SFRP5 to endothelial function in both animal models and human diabetes mellitus proposes that SFRP5 could have an important therapeutic value in the prevention or treatment of atherosclerosis.
